Cargando…

The DURATIONS randomised trial design: Estimation targets, analysis methods and operating characteristics

BACKGROUND: Designing trials to reduce treatment duration is important in several therapeutic areas, including tuberculosis and bacterial infections. We recently proposed a new randomised trial design to overcome some of the limitations of standard two-arm non-inferiority trials. This DURATIONS desi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quartagno, Matteo, Carpenter, James R, Walker, A Sarah, Clements, Michelle, Parmar, Mahesh KB
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851720/ https://www.ncbi.nlm.nih.gov/pubmed/33153304 http://dx.doi.org/10.1177/1740774520944377

Ejemplares similares

Rethinking non-inferiority: a practical trial design for optimising treatment duration
por: Quartagno, Matteo, et al.
Publicado: (2018)

A comparison of different population-level summary measures for randomised trials with time-to-event outcomes, with a focus on non-inferiority trials
por: Quartagno, Matteo, et al.
Publicado: (2023)

An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect
por: Royston, Patrick, et al.
Publicado: (2014)

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
por: Royston, Patrick, et al.
Publicado: (2013)

Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated
por: Royston, Patrick, et al.
Publicado: (2016)

Multiple imputation for discrete data: Evaluation of the joint latent normal model
por: Quartagno, Matteo, et al.
Publicado: (2019)

Substantive model compatible multilevel multiple imputation: A joint modeling approach
por: Quartagno, Matteo, et al.
Publicado: (2022)

Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation
por: Quartagno, Matteo, et al.
Publicado: (2020)

The value of evidence synthesis in randomised controlled trial (RCT) design, conduct and analysis: MRC clinical trials unit (CTU) at UCL experience
por: Tierney, Jayne F, et al.
Publicado: (2015)

A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis
por: Bratton, Daniel J, et al.
Publicado: (2013)

Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome
por: Choodari-Oskooei, Babak, et al.
Publicado: (2013)

A framework for the design and analysis of phase III randomised trials in uncommon diseases
por: Parmar, Mahesh, et al.
Publicado: (2015)

What is the optimal duration, dose and frequency for anti-PD1 therapy of non-small cell lung cancer?
por: Kuah, Chii Yang, et al.
Publicado: (2023)

Survival analysis: coping with non proportional hazards in randomized trials
por: Royston, Patrick, et al.
Publicado: (2011)

Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit
por: Royston, Patrick, et al.
Publicado: (2011)

Multiple imputation for IPD meta‐analysis: allowing for heterogeneity and studies with missing covariates
por: Quartagno, M., et al.
Publicado: (2015)

Adding new experimental arms to randomised clinical trials: Impact on error rates
por: Choodari-Oskooei, Babak, et al.
Publicado: (2020)

How do you design randomised trials for smaller populations? A framework
por: Parmar, Mahesh K. B., et al.
Publicado: (2016)

The need for a cultural shift from two-arm to multi-arm RCTS
por: Sydes, Matthew R, et al.
Publicado: (2013)

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials
por: Dearnaley, David P, et al.
Publicado: (2009)

Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial
por: Choodari-Oskooei, Babak, et al.
Publicado: (2023)

Why restricted mean survival time methods are especially useful for non-inferiority trials
por: Quartagno, Matteo, et al.
Publicado: (2021)

The estimation of duration of maternally-derived antibodies against Akabane, Aino, and Chuzan virus in calves by the receiver operating characteristic analysis
por: IWAMOTO, Jiro, et al.
Publicado: (2020)

A new measure of predictive ability for survival models
por: Choodari-Oskooei, Babak, et al.
Publicado: (2011)

Discrimination-based sample size calculations for multivariable prognostic models for time-to-event data
por: Jinks, Rachel C., et al.
Publicado: (2015)

Assessing the impact of efficacy stopping rules on the error rates under the multi-arm multi-stage framework
por: Blenkinsop, Alexandra, et al.
Publicado: (2019)

The extension of total gain (TG) statistic in survival models: properties and applications
por: Choodari-Oskooei, Babak, et al.
Publicado: (2015)

Severity of Downgaze Palsy in the Context of Disease Duration Could Estimate Survival Duration in Patients With Progressive Supranuclear Palsy
por: Xie, Tao, et al.
Publicado: (2021)

Duration of Bloodless Operations
Publicado: (1875)

Flexible trial design in practice – dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial
por: Sydes, Matthew R, et al.
Publicado: (2011)

A flow cytometric method for estimating S-phase duration in plants
por: Mickelson-Young, Leigh, et al.
Publicado: (2016)

Optimising trial designs to identify appropriate antibiotic treatment durations
por: Pouwels, Koen B., et al.
Publicado: (2019)

Classifying Streamflow Duration: The Scientific Basis and an Operational Framework for Method Development
por: Fritz, Ken M., et al.
Publicado: (2020)

Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome
por: Choodari-Oskooei, Babak, et al.
Publicado: (2013)

A systematic review of randomisation method use in RCTs and association of trial design characteristics with method selection
por: Bruce, Cydney L., et al.
Publicado: (2022)

Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson’s Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer
por: Zeissler, Marie-Louise, et al.
Publicado: (2020)

Sharing data from clinical trials: the rationale for a controlled access approach
por: Sydes, Matthew R, et al.
Publicado: (2015)

A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol
por: Langley, Ruth E., et al.
Publicado: (2016)

How Should We Best Estimate the Mean Recency Duration for the BED Method?
por: Hargrove, John, et al.
Publicado: (2012)

Methods for delivering the UK's multi‐centre prison‐based naloxone‐on‐release pilot randomised trial (N‐ALIVE): Europe's largest prison‐based randomised controlled trial
por: Meade, Angela Mary, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cb8obojggtu2q5ucsogtndlu2i